Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

Privacy has never mattered more.Decentralized money has never matter more.Self-custody has never mattered more.Fiat debasement protection has never mattered more.Digital property rights has never mattered more.Crypto has never mattered more. ...

Disclosure of the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the French Commercial Code and the Article 223-16 of the Règlement général de l’Autorité des marchés financiers (Regulation of the French stock market authority) Company name of the issuer: Renault S.A. 122 - 122 bis Avenue du Général Leclerc 92100 Boulogne-Billancourt (ISIN code: FR0000131906 – RNO) DateTotal number of issued sharesTotal number of voting rights June 30, 2025295,722,284Theoretical num ...

Saudi Arabia is loosening its rules around women’s sports. Seven years ago girls were banned from playing in public; now 70,000 take part in the school soccer league.Where sport leads, society follows https://t.co/1O5Q4yhs6V ...

There's a lot going on in the world of police accountability and yet most of it seems sadly unsurprising. The Department of Justice has now completely reversed course and is asking for one day for the officer who fired 10 shots into the home of Briana Taylor on the night of her death as part of a police raid. We're talking about Brett Hankson.And it's not even a new day. It's time served for the day that the officer got when he was actually arrested. Now, keep in mind, this was the same DOJ that actually in ...

I thought it wouldn't be a problem to go to work as um as long as I did nothing wrong. Um as long as I identified myself, who I was. Um and clearly it didn't matter if I was a citizen or if I was a veteran or if if I identified who I was at all. It didn't matter to them. George Rhett, a 25-year-old Army veteran and United States citizen, describing his ICE arrest to Chris Hayes. He said immigration and customs enforcement agents, smashed his car window and yanked him out of his car before pepper- sprraying ...

Turning back to the case of Bana Taylor as Trump's Justice Department announced on Wednesday that it will seek just one day in prison, time already served, against a Louisville, Kentucky police officer charged in connection with the raid that led to her death in 2020. Joining me now is civil rights attorney. I call him the and many do have joined me uh calling him the attorney general of black America, Attorney Benjamin Crump.Attorney Crump, thank you for being with us. You and I have worked closely with fa ...

Some 10% of the 160,000 children who were adopted by foreigners between China’s legalising of this practice in 1991 and its banning last year were forcibly taken from their birth parents, by one count https://t.co/EZPbZg3GHT ...

People fleeing calamity have a right to seek safety—but that does not mean access to a rich country’s labour market https://t.co/tn4s0pHhms ...